Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study.

about

Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B.Favorable outcome of liver transplantation despite a high hepatitis B virus replication: beyond the limits?

P2860

Q44579921-FAD9ED27-1AAB-4E18-9EDF-C0EDE423C13D Q45413279-2FAAF277-C185-4377-9A71-0005473D1981

P2860

Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study.

Item

http://www.wikidata.org/entity/Q44159624

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Oral ganciclovir for treatment ...... irus infection: a pilot study.

@en

Oral ganciclovir for treatment ...... irus infection: a pilot study.

@nl

type

Item

label

Oral ganciclovir for treatment ...... irus infection: a pilot study.

@en

Oral ganciclovir for treatment ...... irus infection: a pilot study.

@nl

prefLabel

Oral ganciclovir for treatment ...... irus infection: a pilot study.

@en

Oral ganciclovir for treatment ...... irus infection: a pilot study.

@nl

P1476

Oral ganciclovir for treatment ...... irus infection: a pilot study.

@en

P2093

Abdullah Mithat Bozdayi

http://www.w3.org/2001/XMLSchema#string

Cihan Yurdaydin

http://www.w3.org/2001/XMLSchema#string

Hakan Bozkaya

http://www.w3.org/2001/XMLSchema#string

Ozden Uzunalimoglu

http://www.w3.org/2001/XMLSchema#string

Ozlem Erkan

http://www.w3.org/2001/XMLSchema#string

Selim Karayalcin

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.

Hepatitis B infection: pathogenesis and management.

Viral dynamics in hepatitis B virus infection.

Dynamics of hepatitis B virus infection in vivo.

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.

Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels.

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.

Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient.

P304

960-965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/342907

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12355383

http://www.w3.org/2001/XMLSchema#string

Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study.

about

P2860

P2860

Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698